Soligenix Inc. Anticipates Key Catalysts in 2025 for Rare Disease Treatments
Soligenix Inc. is poised for significant advancements in its rare disease treatment pipeline, with key updates expected in 2025 that could impact its stock valuation and the medical community.
Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases, has been highlighted in a recent Zacks Small-Cap Research report for its promising pipeline and upcoming milestones in 2025. The report underscores the company's progress in its phase 3 FLASH2 trial for HyBryte(TM), aimed at treating early-stage cutaneous T cell lymphoma (CTCL), with an enrollment update anticipated in the latter half of 2025 and topline results expected in 2026.
Additionally, Soligenix is set to provide a clinical update in Q3 2025 for an investigator-initiated study evaluating extended HyBryte(TM) treatment. The company also expects topline results from its phase 2a trials for SGX302 in psoriasis and SGX945 in Behcet’s disease during the same period. These developments represent potential catalysts for the company's growth and stock performance, as noted by Zacks.
The Zacks report expresses optimism about Soligenix's prospects, particularly the FLASH2 trial, based on robust interim results from related studies. The psoriasis and Behcet’s disease programs are seen as additional value drivers not currently reflected in the company's share price. For more details, the full report can be accessed here.